

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



August 7, 2026

Company Anicom Holdings, Inc.  
Representative Director Nobuaki Komori  
(Securities Code: 8715 TSE PRIME)  
Inquiries to Norihiko Sakurai  
Corporate Planning Department,  
General Manager

## **Monthly Management Parameters, June 2026**

The following is a summary of the major targets set as the management targets in Anicom Group's pet insurance business and new business initiatives aimed at realizing the vision of becoming a prevention-oriented company.

Monthly Management Parameters, FY2026 (From April 1, 2026 to March 31, 2027)

|                                                                                          | April                       | May                         | June                        | July                   | August                 | September              |
|------------------------------------------------------------------------------------------|-----------------------------|-----------------------------|-----------------------------|------------------------|------------------------|------------------------|
| Net premiums written<br>(previous year)                                                  | 5,431JPYmn<br>(5,134 JPYmn) | 5,730JPYmn<br>(5,424 JPYmn) | 5,552JPYmn<br>(5,220 JPYmn) | JPYmn<br>(5,175 JPYmn) | JPYmn<br>(5,332 JPYmn) | JPYmn<br>(5,387 JPYmn) |
| No. of policies in force<br>(previous year)                                              | 1,397,826<br>(1,297,369)    | 1,405,440<br>(1,308,167)    | 1,411,711<br>(1,318,043)    | (1,326,765)            | (1,337,652)            | (1,347,456)            |
| Renewal rate<br>(previous year)                                                          | 88.5%<br>(88.5%)            | 88.2%<br>(88.2%)            | 88.2%<br>(88.2%)            | %<br>(88.4%)           | %<br>(88.4%)           | %<br>(88.4%)           |
| No. of applicants of Doubutsu<br>Kenkatsu<br>(gut microbiota testing)<br>(previous year) | 22,227<br>(20,749)          | 22,563<br>(23,085)          | 18,195<br>(19,134)          | (20,123)               | (22,258)               | (21,294)               |
| No. of patents held*1<br>(previous year)                                                 | 27<br>(22)                  | 28<br>(22)                  | 30<br>(23)                  | (24)                   | (25)                   | (25)                   |
| JARVIS Tokyo Revenue*2<br>(previous year)                                                | 66,371JPYk<br>(-JPYk)       | 60,449JPYk<br>(-JPYk)       | 61,463JPYk<br>(-JPYk)       | JPYk<br>(-JPYk)        | JPYk<br>(-JPYk)        | JPYk<br>(-JPYk)        |

|                                                                                          | October                | November               | December               | January                | February               | March                 |
|------------------------------------------------------------------------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|-----------------------|
| Net premiums written<br>(previous year)                                                  | JPYmn<br>(5,415 JPYmn) | JPYmn<br>(5,280 JPYmn) | JPYmn<br>(5,376 JPYmn) | JPYmn<br>(5,529 JPYmn) | JPYmn<br>(5,307 JPYmn) | JPYmn<br>(5,518JPYmn) |
| No. of policies in force<br>(previous year)                                              | (1,357,005)            | (1,367,606)            | (1,374,230)            | (1,381,349)            | (1,387,367)            | (1,392,772)           |
| Renewal rate<br>(previous year)                                                          | %<br>(88.5%)           | %<br>(88.7%)           | %<br>(88.5%)           | %<br>(88.5%)           | %<br>(88.7%)           | %<br>(88.6%)          |
| No. of applicants of Doubutsu<br>Kenkatsu<br>(gut microbiota testing)<br>(previous year) | (24,388)               | (21,089)               | (20,426)               | (22,763)               | (20,880)               | (22,437)              |
| No. of patents held* <sup>1</sup><br>(previous year)                                     | (25)                   | (25)                   | (25)                   | (25)                   | (25)                   | (26)                  |
| JARVIS Tokyo Revenue* <sup>2</sup><br>(previous year)                                    | JPYk<br>(5,622 JPYk)   | JPYk<br>(15,041 JPYk)  | JPYk<br>(39,241 JPYk)  | JPYk<br>(31,259 JPYk)  | JPYk<br>(42,629 JPYk)  | JPYk<br>(49,928 JPYk) |

\*1 We disclose the figure as a key figure related to the promotion of BioInsurTech using big data, with the aim of realizing a prevention-oriented company that prevents injuries and illnesses before they occur.

\*2 JARVIS Tokyo Revenue represents the monthly revenue of JARVIS Animal Medical Center Tokyo, an advanced veterinary medical facility that commenced operations in October 2025 as a new strategic pillar. The Company has been disclosing this figure beginning with the April 2026 results.

(Reference) “Monthly Management Parameters” will be disclosed after middle of each month, but it will be disclosed on the same day as the quarterly earnings announcement date for June, September, December, and March.